#ESCCongress – RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
29 Aug, 2021 | 18:19h | UTCEmpagliflozin in Heart Failure with a Preserved Ejection Fraction – New England Journal of Medicine
News release: Trial reports first successful results for heart failure with preserved ejection fraction – European Society of Cardiology
Commentary on Twitter
#FIGARO-DKD #ESCCongress
?in patients w T2D & microalbuminuria & stage 1-4 CKD, finerenone vs placebo led to 13% relative ⬇️in CV events (mostly due to 29%⬇️in HF hospitalizations)
?~2/3 pts +microalbuminuria w normal GFR:? is to✔️in T2D#ESCCongress https://t.co/8oT5s8KjT0 pic.twitter.com/fQbmUzPasD— Ritu Thamman MD (@iamritu) August 28, 2021